Percutaneous Aortic Valve IDE Approval Rests On Clearer Criteria – Edwards
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will work with FDA on crafting an acceptable definition for "high-risk patients" to meet an investigational device exemption approval goal of early 2005 for its percutaneous aortic valve, the firm said in a Dec. 3 investor conference
You may also be interested in...
Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval
Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.